- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Bev H. Lorell, M.D. (Beverly)
News 3 results
In the News · Source: FDAnews
February 14, 2023
Beverly Lorell comments on issues of data integrity and why it represents high stakes for both sponsors and clinical investigators
In the News · Source: FDAnews
October 31, 2022
Mark Brown, Pete Leininger and Beverly Lorell explain how the COVID-19 pandemic has upended the conduct of clinical trials in a number of ways
Cases & Deals
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
Events 18 results
Webinar
November 30, 2022
Are You Prepared? FDA’s Proposed Rules to Modify Protection of Human Subjects and IRB Oversight
Conference
November 1, 2022
Pharmaceutical University 2022
Webinar
September 9, 2021
14th Annual King & Spalding Medical Device Summit
Insights 22 results
Client Alert
March 7, 2023
FDA Issues Draft Guidance on “External Controls” in Clinical Trials to Support Safety and Efficacy of a Drug
Client Alert
November 14, 2022
FDA (Finally!) Issues Proposed Rule to Amend FDA Regulations on the Protection of Human Subjects and Institutional Review Boards
Article · Source: WCG CenterWatch
November 1, 2022
Clinical Data Integrity: FDA and DOJ Enforcement Priorities
Client Alert
February 8, 2022
Europe - Between The EU Clinical Trials Regulation And The UK Guideline On Clinical Trials